Rifaximin-α use is associated with improved muscle mass in patients with cirrhosis

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

158

Figures (1-1)

Tables (1-4)

Sum=203

Publishing Process of This Article

Item

Count

Browse

Download

Sum=25

Apr 27, 2025 (publication date) through Apr 28, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Hepatol. Apr 27, 2025; 17(4): 104056
Published online Apr 27, 2025. doi: 10.4254/wjh.v17.i4.104056

Figure 1 Patient identification flowchart. CT: Computed tomography.

Citation: Worland T, Hey P, Wong D, Apostolov R, Chan RK, Sinclair M, Gow P. Rifaximin-α use is associated with improved muscle mass in patients with cirrhosis. World J Hepatol 2025; 17(4): 104056
URL: https://www.wjgnet.com/1948-5182/full/v17/i4/104056.htm
DOI: https://dx.doi.org/10.4254/wjh.v17.i4.104056